Figures 2A, B illustrated a notable increase in UBE2B expression in tumor samples obtained from various cancers, including CHOL, COAD, ESCA, KIRC, LIHC, and STAD. Similarly, in a paired pan-cancer analysis, UBE2B expression was found to be consistently high in the majority of tumor samples, including ESCA (Figures 2C, D). Furthermore, the expression of UBE2B was observed to be correlated with unfavorable prognosis in multiple tumor types, impacting both overall survival (OS) and disease-specific survival (DSS) (Figure 3). The gene discussed is UBE2B; the disease is cancer.